Cell and Gene Therapy

Axovant rely on new gene therapy, Rise in Shares  Roivant Neuro Company has licensed Oxford Biomedica’s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson’s disease (PD). Spark Therapeutics’ Former CTO Fraser Wright, Ph.D has been hired as its new CTO. Axovant expects to stimulate a phase 1/2 dose escalation study in patients having PD. Axovant paid $30 million to gain Lenti-PD and ProSavin (a lentiviral vector-based gene therapy for PD). Shares jumped around 100% on 6th june, striking around $3.50. CAR-T treatments can be secured by Amgen-developed RA drug CAR-T cells Gilead’s Yescarta and Novartis’s Kymriah, used to treat blood cancers can increase the risk of a...